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ABSTRACT
Objective Symptoms and clinical course during 
inlammatory bowel disease (IBD) vary among 
individuals. Personalised care is therefore essential 
to effective management, delivered by a strong 
patient-centred multidisciplinary team, working 
within a well-designed service. This study aimed to 
fully rewrite the UK Standards for the healthcare 
of adults and children with IBD, and to develop an 
IBD Service Benchmarking Tool to support current 
and future personalised care models.
Design Led by IBD UK, a national 
multidisciplinary alliance of patients and 
nominated representatives from all major 
stakeholders in IBD care, Standards requirements 
were deined by survey data collated from 689 
patients and 151 healthcare professionals. 
Standards were drafted and reined over three 
rounds of modiied electronic-Delphi.
Results Consensus was achieved for 59 Standards 
covering seven clinical domains; (1) design and 
delivery of the multidisciplinary IBD service; 
(2) prediagnostic referral pathways, protocols 
and timeframes; (3) holistic care of the newly 
diagnosed patient; (4) lare management to 
support patient empowerment, self-management 
and access to specialists where required; 
(5) surgery including appropriate expertise, 
preoperative information, psychological support 
and postoperative care; (6) inpatient medical care 
delivery (7) and ongoing long-term care in the 
outpatient department and primary care setting 
including shared care. Using these patient-centred 
Standards and informed by the IBD Quality 
Improvement Project (IBDQIP), this paper presents 
a national benchmarking framework.
Conclusions The Standards and Benchmarking 
Tool provide a framework for healthcare 
providers and patients to rate the quality of their 
service. This will recognise excellent care, and 
promote quality improvement, audit and service 
development in IBD.
INTRODUCTION
Over 500 000 people in the UK are 
estimated to be affected by inflamma-
tory bowel disease (IBD).1 2 As lifelong, 
relapsing and complex conditions, medical 
costs associated with the care of the prin-
cipal forms of IBD (Crohns disease and 
ulcerative colitis) can be comparable with 
those for major chronic diseases such as 
diabetes mellitus and cancer. The esti-
mated average cost of treating a patient 
with ulcerative colitis is £3084 per year 
and that of treating a patient with Crohns 
disease is £6156 per year.3 While surgery 
rates appear to be decreasing for Crohns 
disease,4 any associated reduction in NHS 
costs may be offset by increased use of 
biological therapies.5
The first UK Service Standards for the 
healthcare of people who have IBD6 were 
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developed by patient and professional associations and 
were published in 2009 in response to a UK-wide audit 
highlighting significant variation in care.7 The IBD 
Standards defined what was required in terms of staff, 
support services, organisation, patient education and 
audit to provide integrated, high-quality IBD services. 
The 2013 updated IBD Standards8 underpinned the 
2015 National Institute for Health and Care Excellence 
(NICE) quality standard on IBD (QS81)9 and were an 
integral component of the IBD Quality Improvement 
Programme in the UK10 supported by the Royal College 
of Physicians until 2015.
The fourth and final round of the UK IBD Audit in 
2014 has demonstrated improvements in several areas 
of service provision, including increased numbers 
of IBD nurse specialists and dietitians and reduced 
mortality.11 12 However, it has also shown continuing 
variation in the quality and responsiveness of health-
care for people with IBD in the UK. Considerable issues 
have been highlighted in a number of areas, in particular, 
speed of access to specialist assessment at referral and 
relapse; appropriate provision for IBD nurse specialists, 
dietetic access and psychological support; patient educa-
tion opportunities and involvement of patients in service 
planning. Previous rounds of audit have also shown a 
need for improved communication between primary 
care and secondary care.13
Recent work in the UK by Crohns & Colitis UK has 
shown that factors such as loneliness, degree of control 
and involvement in care are significantly associated with 
active disease, a reduction in quality of life and low life 
satisfaction.14 The considerable psychosocial impact 
of IBD on education, careers, social and intimate well-
being is well-documented in quality of life studies.15 16 
Furthermore, patient surveys have drawn attention to 
concerns around delays in diagnosis, timeliness of review 
and treatment, access to appropriate inpatient facilities, 
coordination and continuity of care.17 The surveys also 
highlight needs relating to patients understanding about 
their condition, available treatment options and involve-
ment in shared decision-making.
The individual impact of IBD and experience of 
IBD services, together with an increasing focus on 
personalised care in the NHS6 across the UK, under-
lines the need for quality improvement methodolo-
gies in IBD. Future service design and development 
must be patient-centred and must include mechanisms 
to capture service outcomes that enable patients to 
monitor impact and shape solutions in the delivery of 
IBD services. The National Cancer Patient Experience 
Survey 2017 demonstrated significant improvement 
on 21/52 questions compared with the previous years 
results,18 highlighting the potential benefit of this type 
of approach if used to shape future UK IBD care.
Therefore, a complete revision of the UK IBD Standards 
was considered essential. This is particularly important 
due to the significant changes in IBD management since 
2013, such as the complex range of new medical therapy 
options, the growing use of minimally invasive surgical 
techniques in the UK; the increased use, the general 
acceptance and use of new web-based communication 
technology; and recognition of the central importance of 
involving the patient in decision-making.
METHODS
The IBD Standards 2019 methodology was designed 
to align with the 2019 British Society of Gastroenter-
ology (BSG) IBD guidelines19 and the 2018 Associa-
tion of Coloproctology of Great Britain and Ireland 
(ACPGBI) IBD surgical guidelines.20 In addition, the 
process considered other relevant professional and 
NICE guidelines.
IBD UK and national stakeholders
The Standards development process was led from its 
inception by IBD UK, a national multidisciplinary 
alliance of nominated representatives from patient 
and professional organisations, with integrated 
patient involvement on the Standards Development 
Group and at all stages of the development process. 
Representation from all devolved nations ensured 
standards were applicable throughout the UK. The 
following organisations/stakeholders were represented 
by IBD UK (author affiliations or membership are 
denoted by initials):
 Ź Association of Coloproctology of Great Britain and 
Ireland: AA, SJB, AD, JD and OF
 Ź British Association for Parental and Enteral Nutrition: 
NB
 Ź British Dietetic Association: AB and KK
 Ź British Society of Gastrointestinal and Abdominal Radi-
ology: GB and SAT
 Ź British Society of Gastroenterology: IDA, ABH, CAL and 
AM
 Ź British Society of Paediatric Gastroenterology, Hepa-
tology and Nutrition: JE and RM
 Ź CICRA: NP
 Ź Crohns & Colitis UK: GB, JG and RK
 Ź UK IBD Registry: SB and FC
 Ź Ileostomy & Internal Pouch Association: AD
 Ź Primary Care Society for Gastroenterology: CA and KJB
 Ź Royal College of General Practitioners: KJB
 Ź Royal College of Nursing: KC, VG and LY
 Ź Royal College of Pathologists: RMF
 Ź Royal College of Physicians: IDA, ABH, CAL and SW
 Ź Royal Pharmaceutical Society: AStCJ
 Ź UK Clinical Pharmacy Association: AStCJ and UM
Online healthcare professional and patient surveys
The use and impact of previous iterations of the IBD 
Standards on healthcare professionals was assessed by 
an anonymous online survey to guide development of 
the Standards revision. An online survey of patients 
with IBD was also conducted. The Standards Develop-
ment Group also reviewed the 2013 IBD Standards to 
formally identify where recommendations for service 
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table 1 Thematic feedback from healthcare professionals and patients regarding use of previous IBD Standards and areas for inclusion 
for 2019 IBD Standards
Healthcare professional survey (n=151) Patient survey (n=689)
Practical examples of use of IBD Standards in clinical practice
 Ź Funding and business cases for staff (IBD nurse specialists, dietitian, 
psychologist, administrator, improved bed:toilet ratio).
 Ź Funding and protected time to use UK IBD Registry.
 Ź Support for service improvement (establishment of multidisciplinary team, 
rapid biologics initiation, joint gastroenterology/surgical clinic, fast track for 
perianal Crohn surgery).
 Ź Increased patient support (patient advice line, patient panel, annual patient 
open day).
Suggestions for inclusion in 2019 IBD Standards
 Ź Guidance on appropriate and accessible information, communication 
and support for patients at all points to improve understanding and self-
management, enhance a sense of personal control/empowerment and 
alleviate the isolation many feel.
 Ź Mental health referral pathways/training to give emotional support and 
regular mental health assessments from diagnosis.
 Ź An emphasis on holistic treatment and care, including wider symptoms 
such as pain and fatigue, joint and skin conditions.
 Ź Focus on what constitutes effective shared and coordinated care, 
including between different specialists, primary and secondary care and 
accident and emergency and the IBD team.
 Ź Strengthen sections outlining opportunities for patient and carer 
involvement in improving IBD services.
 Ź Clear recommendations on time frames for diagnosis, access to advice, 
investigations, medication and surgery.
 Ź A personalised care plan for every person with IBD that they jointly 
develop and have access to, which includes mental health, dietetic 
support, lifestyle advice, medication reviews, regular monitoring and 
alternatives to medicines.
 Ź Greater emphasis on preventing flares, including education on 
identifying signs and development of individual plans around 
prevention.
 Ź Guidance on what shared decision-making should look like, particularly 
in relation to medications.
Suggestions for 2019 IBD Standards
 Ź Strengthened focus on the role of primary care to enable more seamless 
care.
 Ź Increased detail relating to surgery.
 Ź Greater clarity around delivery of biologics services.
 Ź More specific requirements for the level of dietetic service that should be 
provided.
 Ź Improved emphasis on paediatric and adolescent IBD.
 Ź Increased focus on involvement of service users.
 Ź Expanded methods to help patients stay well and to prevent flares as far as 
possible.
 Ź More accessible, user-friendly and patient journey orientated.
 Ź Resources to support service development, including business case 
templates and patient stories, benchmarking toolkit and links to clinical 
guidance.
 Ź Importance of outcomes (including quality of life) and quality metrics, 
linkages with IBD Registry and RCP QI programme.
IBD, inlammatory bowel disease; QI, quality improvement; RCP, Royal College of Physicians.
design and delivery should be updated or reinforced 
in light of evolving evidence-based clinical practice, 
patient perception and expert opinion.
IBD Standards consensus development and e-Delphi
Informed by the above patient and healthcare profes-
sional surveys and critical review of prior Standards 
iterations, the Standards Development Group then 
drafted statements. A reference group of 17 patients/
carers from throughout the UK, who had previous 
experience of activity related to IBD service improve-
ment, gave feedback on the Standards working docu-
ment. The IBD Standards were then refined across 
three rounds of anonymised modified e-Delphi voting, 
developing recommendations for optimal service 
design and delivery and in relation to quality improve-
ment or key performance measures; 28 voters assessed 
each statement on a 5-point scale (strongly agree (SA), 
agree (A), neither agree nor disagree (N), disagree (D) 
or strongly disagree (SD)). After each round of voting, 
the Standards were assessed and, if necessary, redrafted 
based on voter feedback. Agreement was defined as a 
score of agree or strongly agree. Consensus agree-
ment was defined as >80% agreement from the group. 
e-Delphi voters represented patients and all profes-
sional groups, including specialist nurses, gastroenter-
ologists, colorectal surgeons, paediatricians, general 
practitioners (GPs), radiologists, pathologists, dieti-
tians and pharmacists. Voters were geographically 
representative of the UK.
Development of the IBD Benchmarking Tool
Led by IBD UK, a Benchmarking Development Group 
identified the core components of service delivery, 
based on established good practice and/or multidisci-
plinary expert consensus at grading levels AD to cover 
the range of IBD Standards statements. The service 
self-assessment tool was tested in a range of services 
and refined based on feedback. Development of the 
patient survey was led by Crohns & Colitis UK for 
IBD UK, with questions mapped to the IBD Standards 
statements and graded AD in line with the service 
self-assessment tool. Initial questions were refined 
following feedback from a reference group of patients 
and parents/carers and were further cognitively tested 
through a focus group and telephone interviews.
RESULTS
Online patient and health professional surveys
An online survey of 151 healthcare professionals 
(65 IBD nurse specialists, 60 gastroenterologists, 
5 colorectal surgeons, 6 specialist pharmacists, 7 
dietitians, 4 GPs, 2 nurse endoscopists, 1 radiologist 
and one trainee physiologist) assessed the usage and 
impact of previous iterations of the IBD Standards. 
79.7% (n=122) reported that the document helped 
them to plan and develop their local service, 71.9% 
(n=110) said they helped to understand what a 
great service should look like, and 81.7% (n=125) 
said the Standards had helped with business case 
development for new resources. A range of practical 
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Figure 1 2019 IBD Standards sections: seven sections following the patient journey from referral through to ongoing long-term care. Key 
considerations for optimal service design and delivery are shown grouped according to these sections. GI, gastrointestinal; IBD, inlammatory bowel 
disease.
examples of the use of previous versions of the IBD 
Standards and suggestions for inclusion in this iter-
ation of the Standards were cited by respondents. A 
thematic summary of these responses is presented in 
table 1.
An online survey carried out by IBD UK of 689 
patients (45% Crohns disease, 40% ulcerative 
colitis, 3.3% IBDU, 0.7% microscopic colitis and 2% 
other) was assessed to determine patient preference 
for content of the IBD Standards and what would 
make the greatest impact on patient care. Thematic 
conclusions from this survey are summarised in 
table 1.
IBD Service Standards
The 2019 IBD Standards were created to reflect the 
central position and importance of the patient in 
service design and delivery. In particular, a strength-
ened focus on surgery, primary care, paediatrics 
and patient empowerment was identified relative to 
previous iterations of the Standards. Accompanying 
tools and resources and a benchmarking process to 
support implementation were also advocated. The 
Standards development process therefore set out to 
follow the patient journey across seven sections from 
referral, through diagnosis, surgical and medical treat-
ment, to long-term management of IBD (figure 1). 
The consensus IBD Standards following three rounds 
of modified e-Delphi are presented in boxes 17 
according to each of the seven sections.
IBD Service Benchmarking Tool
In the online survey of 151 healthcare professionals, 
over 90% of respondents agreed that a benchmarking 
tool would be useful to support implementation of the 
IBD Standards. A new web-based tool has been devel-
oped to address this need (figure 2). The tool bench-
marks against the revised IBD Standards and builds on 
the approach undertaken by the IBD Quality Improve-
ment Project (IBD QIP) tool10 and the endoscopy 
Global Rating Scale.21 The unique strength of this 
tool is that both patient experience and service perfor-
mance can be measured and benchmarked. This is 
achieved by a web-based self-assessment completed by 
the healthcare team and a different survey completed 
by patients.
Within the Benchmarking Tool, the IBD Standards 
core statements (boxes 17) are represented across 
four domains of access, coordinated care, patient 
empowerment and quality. Each domain is subdi-
vided into diagnosis, treatment, ongoing care and 
IBD service, with corresponding questions on both 
the patient survey and service self-assessment tool. 
Based on a set of agreed descriptors, gradings can be 
generated based on the results of the patient survey 
and through the service self-assessment process, 
ranging from excellent, proactive to minimal, inad-
equate care. Services will thereby be able to identify 
areas that clearly require quality improvement and to 
make the case for additional resources where needed. 
The benchmarking tool will enable clinical teams to 
compare self-assessment of service performance with 
patient experience across all domains, as well as with 
the UK average, the UK devolved nation average and 
the previous years results for the service. Additional 
resources will be available through the IBD UK website 
to support quality improvement (https:// ibduk. org/).
copyright.
 o
n
 N
ovem
ber 20, 2019 at Sheffield Uni Consortia. Protected by
http://fg.bmj.com/
Frontline G
astroenterol: first published as 10.1136/flgastro-2019-101260 on 24 July 2019. Downloaded from
 
Kapasi R, et al. Frontline Gastroenterology 2019;0:1–10. doi:10.1136/lgastro-2019-101260  5
PROFESSIONAL MATTERS
Box 1 the iBD service
Statement 1.1: Patients should be cared for by a defined 
IBD multidisciplinary team led by a named consultant adult 
or paediatric gastroenterologist (consensus 96%: SA 71%, A 
25%, N 4%).
Statement 1.2: Multidisciplinary team meetings 
should take place regularly to discuss appropriate patients 
(consensus 100%: SA 89%, A 11%).
Statement 1.3: Protocols should be in place, is which 
clearly define the local transition service and the personnel 
responsible (consensus 100%: SA 64%, A 36%).
Statement 1.4: The IBD service should have a leadership 
team that includes a senior clinician, an IBD nurse specialist 
and a manager who has responsibility for managing, 
monitoring and developing the service (consensus 100%: SA 
61%, A 39%).
Statement 1.5: The IBD leadership team should work 
with an expert pharmacist in IBD to ensure good medicines 
governance, including medicine optimisation and cost-
effectiveness (consensus 100%: SA 57%, A 43%).
Statement 1.6: IBD teams should promote continuous 
quality improvement and participate in local and national 
audit (consensus 100%: SA 68%, A 32%).
Statement 1.7: Patients and parents/carers should have 
a voice and direct involvement in the development of the 
service (consensus 100%: SA 64%, A 36%).
Statement 1.8: All patients with confirmed IBD should 
be recorded in an electronic clinical management system 
and data provided to the national IBD Registry (consensus 
89%: SA 46%, A 43%, N 11%).
Statement 1.9: Clear information about IBD, the local 
IBD service and patient organisations should be accessible 
in outpatient clinics, wards, endoscopy and day care areas 
(consensus 96%: SA 57%, A 39%, SD 4%).
Statement 1.10: Endoscopic assessment and ultrasound/
MRI/CT/contrast studies should be accessible within 4 
weeks, and within 24 hours where patients are acutely 
unwell or require admission to the hospital (consensus 
100%: SA 50%, A 50%).
Statement 1.11: Histological processing and reporting 
should take place routinely within five working days or 
within two working days for reporting of urgent biopsy 
samples (consensus 100%: SA 61%, A 39%).
Statement 1.12: Agreed protocols should be in place for 
pre-treatment tests, vaccinations, prescribing, administration 
and monitoring of immunomodulator and biological 
therapies (consensus 100%: SA 64%, A 36%).
Statement 1.13: Patients should be fully informed 
about the benefits and risks of, and the alternatives to, 
immunomodulator and biological therapies, including 
surgery (consensus 100%: SA 82%, A 18%).
Statement 1.14: Patients receiving immunomodulator 
and biological therapies should be offered vaccinations in 
accordance with clinical guidelines (consensus 100%: SA 
57%, A 43%).
Statement 1.15: All forms of nutritional therapy should 
be available to patients with IBD, where appropriate, 
including exclusive enteral nutrition for Crohn’s disease 
and referral to services specialising in parenteral nutrition 
(consensus 100%: SA 71%, A 29%).
Continued
Box 1 continued
Statement 1.16: All members of the IBD team 
should develop competencies and be educated to a level 
appropriate for their role, with access to professional 
support and supervision (consensus 96%: SA 68%, A 28%, 
N 4%).
Statement 1.17: IBD services should encourage and 
facilitate involvement in multidisciplinary research through 
national or international IBD research projects and registries 
(consensus 100%: SA 50%, A 50%).
A, agree; IBD, inflammatory bowel disease; N, neither agree nor disagree; SA, 
strongly agree; SD, strongly disagree.
Box 2 Pre-diagnosis
Statement 2.1: Clear pathways and protocols for 
investigating children and adults with persistent lower 
gastrointestinal symptoms should be agreed between 
primary care and secondary care, and should include 
guidance on the use of faecal biomarker tests in primary 
care to aid rapid diagnosis (consensus 96%: SA 57%, A 39%, 
N 4%).
Statement 2.2: Patients who are referred with suspected 
IBD should be seen within 4 weeks, or more rapidly if 
clinically necessary (consensus 100%: SA 57%, A 43%).
Statement 2.3: Patients presenting with acute severe 
colitis should be admitted to a centre with medical and 
surgical expertise in managing IBD that is available at all 
times (consensus 100%: SA 68%, A 32%).
Statement 2.4: All patients should be provided with 
a point of contact and clear information about pathways 
and timescales while awaiting the outcome of tests and 
investigations (consensus 100%: SA 64%, A 36%).
A, agree; IBD, inflammatory bowel disease; N, neither agree nor disagree; SA, 
strongly agree.
DISCUSSION
The development of these IBD Standards was essential 
as a benchmark against which IBD care can be meas-
ured. Compared with the second UK IBD Standards 
from 2013, the 2019 Standards differ substantially 
both in structure (reflecting the patient journey) and 
in content, as a result of substantial changes in service 
delivery in the last 6 years. The Standards reflect the 
increasing complexity of IBD management: the need 
for pre-treatment safety screening and therapeutic 
monitoring; the importance of shared decision-making 
between the IBD health professional team and the 
patient; the increasing involvement of Allied Health-
care Professionals, such as dietitians, psychologists and 
pharmacists, in the management of chronic disease 
patients; the need for partnership between hospi-
tals, primary care and the patient in the delivery of 
care; and the growing use of technology to improve 
communication and patient education.
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Box 3 newly diagnosed
Statement 3.1: All newly diagnosed patients with IBD 
should be seen by an IBD specialist and enabled to see an 
adult or paediatric gastroenterologist, IBD nurse specialist, 
specialist gastroenterology dietitian, surgeon, psychologist 
and expert pharmacist in IBD as necessary (consensus 100%: 
SA 75%, A 25%).
Statement 3.2: After diagnosis, all patients should have 
full assessment of their disease, nutritional status, bone 
health and mental health, with baseline infection screen, in 
order to develop a personalised care plan (consensus 100%: 
SA 43%, A 57%).
Statement 3.3: Patients should be supported to make 
informed, shared decisions about their treatment and care 
to ensure these take their preferences and goals fully into 
account (consensus 100%: SA 68%, A 32%).
Statement 3.4: After diagnosis, all outpatients with IBD 
should be able to start a treatment plan within 48 hours for 
moderate to severe symptoms and within 2 weeks for mild 
symptoms (consensus 100%: SA 54%, A 46%).
Statement 3.5: Patients should be signposted to 
information and support from patient organisations 
(consensus 100%: SA 70%, A 30%).
Statement 3.6: General practitioners should be informed 
of new diagnoses and the care plan that has been agreed 
within 48 hours (consensus 100%: SA 43%, A 57%).
A, agree; IBD, inflammatory bowel disease; SA, strongly agree.
Box 4 Flare management
Statement 4.1: Local treatment protocols and clear 
pathways should be in place for the management of patients 
with IBD experiencing flares and should include advice for 
primary care (consensus 96%: SA 71%, A 25%, N 4%).
Statement 4.2: All patients with IBD should be provided 
with clear information to support self-management and 
early intervention in the case of a flare (consensus 100%: SA 
64%, A 36%).
Statement 4.3: Rapid access to specialist advice should 
be available to patients to guide early flare intervention, 
including access to a telephone/email advice line with 
response by the end of the next working day (consensus 
100%: SA 79%, A 21%).
Statement 4.4: Patients with IBD should have access to 
review by the IBD team within a maximum of five working 
days and should be able to escalate/start a treatment plan 
within 48 hours of review (consensus 100%: SA 61%, 39%).
Statement 4.5: Steroid treatment should be managed 
in accordance with guidelines and audited on an ongoing 
basis, with clear guidance to primary care (consensus 100%: 
SA 68%, A 32%).
A, agree; IBD, inflammatory bowel disease; N, neither agree nor disagree; SA, 
strongly agree.
Box 5 Surgery
Statement 5.1: Patients should have access to coordinated 
surgical and medical clinical expertise, including regular 
combined or parallel clinics with a specialist colorectal 
surgeon (paediatric colorectal surgeon where appropriate) 
and IBD gastroenterologist (consensus 100%: SA 64%, A 
36%).
Statement 5.2: Elective IBD surgery should be performed 
by a recognised colorectal surgeon (paediatric colorectal 
surgeon where appropriate) who is a core member of the 
IBD team in a unit where such operations are undertaken 
regularly (consensus 96%: SA 75%, A 21%, D 4%).
Statement 5.3: In the absence of relevant local expertise, 
paediatric patients or adult patients requiring complex 
surgery should be referred to a specialist unit (consensus 
100%: SA 71%, A 29%).
Statement 5.4: Patients with IBD being considered for 
surgery should be provided with information in a format 
and language they can easily understand to support shared 
decision-making and informed consent and should be 
offered psychological support (consensus 100%: SA 75%, A 
25%).
Statement 5.5: Prior to elective surgery, a full 
assessment and optimisation of medical treatment and 
physical condition should be undertaken to minimise risk of 
complications and aid postoperative recovery (consensus 
100%: SA 75%, A 25%).
Statement 5.6: Patients should be counselled about 
laparoscopic resection as an option, when appropriate, in 
accordance with clinical guidelines (consensus 100%: SA 
71%, A 29%).
Statement 5.7: Patients and parents/carers should be 
provided with information about postoperative care before 
discharge, including wound and stoma care, and offered 
psychological support (consensus 100%: SA 64%, A 36%).
Statement 5.8: Elective surgery for IBD should be 
performed as soon as the patient’s clinical status has been 
optimised and within 18 weeks of referral for surgery 
(consensus 96%: SA 57%, A 39%, SD 4%).
A, agree; D, disagree; IBD, inflammatory bowel disease; SA, strongly agree; 
SD, strongly disagree.
The Standards complement the recently published 
BSG and ACPGBI IBD guidelines.19 20 While these 
guidelines provide the evidence base and detail 
of current management, the Standards define a 
high-quality IBD service, including a number of objec-
tive measures of quality. This provides a cohesive and 
accessible framework for service development. The 
IBD Standards align with the 2015 NICE Quality Stan-
dard,9 providing much greater detail to support effec-
tive delivery of this.
The strengths of these Standards include the process 
by which they were developed. A strong expert 
consensus was achieved through a rigorous approach 
with representation across all relevant professional 
disciplines and UK stakeholders in IBD care, in addi-
tion to consistent input from patients and their organ-
isations. The role of the patient organisation Crohns 
& Colitis UK in leading their development ensures 
that the primary focus is on the patient and their 
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Box 6 inpatient care
Statement 6.1: Patients requiring inpatient care relating to 
their IBD should be admitted directly, or transferred within 
24–48 hours, to a designated specialist ward area under the 
care of a consultant gastroenterologist and/or colorectal 
surgeon (consensus 97%: SA 61%, A 36%, D 3%).
Statement 6.2: Where ensuite rooms are not available, 
inpatients with IBD should have a minimum of one easily 
accessible toilet per three beds on a ward (consensus 97%: 
SA 61%, A 36%, N 3%).
Statement 6.3: Inpatients with IBD must have 24-hour 
rapid access to critical care services if needed (consensus 
97%: SA 79%, 18%, N 3%).
Statement 6.4: Children and adults admitted as 
inpatients with acute severe colitis should have daily review 
by appropriate specialists (consensus 96%: SA 75%, A 21%, 
N 4%).
Statement 6.5: For patients with acute severe colitis, 
stool culture and Clostridium difficile assay should be 
performed on admission to exclude infectious causes of 
colitis (consensus 100%: SA 71%, A 29%).
Statement 6.6: For patients admitted with acute severe 
colitis, limited flexible sigmoidoscopy, when indicated, 
should be performed without bowel preparation by an 
experienced endoscopist (consensus 100%: SA 64%, A 
36%).
Statement 6.7: All patients with acute severe colitis 
not settling on intravenous steroids should be assessed 
regularly by a consultant adult/paediatric colorectal surgeon 
and a decision made with the patient and adult/paediatric 
gastroenterologist on day three to escalate to rescue therapy 
or undertake a colectomy (Consensus 93%: SA 61%, A 32%, 
N 4%, D 3%).
Statement 6.8: On admission, patients with IBD should 
have an assessment of nutritional status, mental health 
and pain management using validated tools, and should be 
referred to services and support as appropriate (consensus 
100%: SA 50%, A 50%).
Statement 6.9: All inptients with IBD should have access 
to an IBD nurse specialist (consensus 100%: SA 71%, A 
29%).
Statement 6.10: All inpatients with IBD should have 
their prescribed and over the counter medications reviewed 
on admission by a pharmacist who has access to an 
expert pharmacist in IBD for advice, with regular review of 
medications during their inpatient stay and at discharge 
(consensus 100%: SA 46%, A 54%).
Statement 6.11: Clear written information about 
follow-up care and prescribed medications should be 
provided before discharge from the ward and communicated 
to the patient’s IBD clinical team and GP within 48 hours of 
discharge (consensus 100%: SA 57%, A 43%).
A, agree; D, disagree; IBD, inflammatory bowel disease; N, neither agree nor 
disagree; SA, strongly agree.
Box 7 Ongoing care and monitoring
Statement 7.1: A personalised care plan should be in place 
for every patient with IBD, with access to an IBD nurse 
specialist and telephone/email advice line (consensus 97%: 
SA 61%, A 36%, N 3%).
Statement 7.2: Patients should be supported in self-
management, as appropriate, through referral or signposting 
to education, groups and support (consensus 100%: SA 
61%, A 39%).
Statement 7.3: Clear protocols should be in place for the 
supply, monitoring and review of medication across primary 
and secondary care settings (consensus 100%: SA 54%, A 
46%).
Statement 7.4: Pain and fatigue are common symptoms 
for patients with IBD and should be investigated and 
managed using a multidisciplinary approach including 
pharmacological, non-pharmacological and psychological 
interventions where appropriate (consensus 100%: SA 61%, 
A 39%).
Statement 7.5: Any reviews and changes of treatment 
in primary or secondary care should be clearly recorded 
and communicated to all relevant parties within 48 hours 
(consensus 100%: SA 50%, A 50%).
Statement 7.6: Patients or parents/carers should be 
offered copies of clinical correspondence relating to their/
their child’s treatment and care (consensus 100%: SA 61%, 
A 39%).
Statement 7.7: All patients with IBD should be 
reviewed at agreed intervals by an appropriate healthcare 
professional, and relevant disease information should be 
recorded (consensus 100%: SA 64%, A 36%).
Statement 7.8: A mechanism should be in place to 
ensure that colorectal cancer surveillance is carried out in 
line with national guidance and that patients and parents/
carers are aware of the process (consensus 100%: SA 68%, 
A 32%).
A, agree; IBD, inflammatory bowel disease; N, neither agree nor disagree; SA, 
strongly agree.
experience of care. Patient feedback was obtained at 
all stages of Standards development.
The Standards are laid out in an accessible form and 
cover many aspects of IBD service delivery that can 
be measured. Two tools were developed to assess the 
service: the benchmarking tool designed for profes-
sionals IBD service self-assessment and the survey tool 
designed for patients. Assessing a service both from the 
providers perspective and from that of the patients 
treated within that service is unique in IBD and may 
create an important tension for change in the absence 
of system-wide levers for service development.
There are limitations in the breadth of the evidence 
base used in formulating these Standards. For example, 
there are no data to validate the appropriate maximum 
time interval within which treatment can be started 
safely. However, the focus has been to define targets 
that are acceptable to patients and appropriate to the 
constraints of the NHS while being relevant also to 
other healthcare systems. The value of the IBD Stan-
dards is dependent on their implementation. The Stan-
dards define criteria that may not be achievable by 
every IBD service, but their purpose is to encourage 
service quality improvement. Fundamental to this is 
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Figure 2 The IBD Service Benchmarking Tool. The 2019 IBD 
Standards form the basis for a web-based benchmarking tool with 
corresponding healthcare professional self-assessment and patient 
survey portals. Within this system, IBD services will be able to assess 
their own performance according to the Standards and see how they 
benchmark against other regional and national services. Healthcare 
professional self-assessment of their service can be presented 
alongside patient survey results for the same service across a range of 
domains. Quality improvement, personalised care and shared decision-
making will be promoted through a range of online support tools, 
guidelines and case studies. IBD, inlammatory bowel disease.
Signiicance of this study
What is already known about this subject?
 Ź Inflammatory bowel disease (IBD) is a chronic 
relapsing remitting condition that affects 500 000 
people or more in the UK. The clinical features, 
symptoms and impact of Crohn’s disease and 
ulcerative colitis on the patient are highly variable and 
complex and may change over time.
 Ź The 2009 and 2013 UK IBD Standards were developed 
to support service design, development and quality 
improvement in light of UK-wide audit data highlighting 
significant variations in the standards of IBD care. While 
this has led to demonstrable improvements in care 
provision, audit data from 2014 demonstrated continued 
inequalities.
 Ź This has highlighted the need for multidisciplinary 
and patient-centred service design and care provision 
in order to provide personalised care, in particular, 
access to specialist assessment at referral and relapse; 
appropriate provision for IBD nurse specialists, 
dietetic and psychological support; patient education 
opportunities and involvement of patients in service 
planning.
What does this study add?
 Ź Led by IBD UK, a multidisciplinary and patient 
representative working group, this study represents an 
entire rewrite of the UK IBD Standards.
 Ź Underpinned by extensive qualitative survey response 
from patients and healthcare professionals, three rounds 
of modified e-Delphi have produced 59 consensus 
Standards grouped around the patient journey 
covering service setup, multidisciplinary delivery, 
patient information, empowerment, shared care and 
self-management.
 Ź Informed by the new Standards and the IBD Quality 
Improvement Project, a service Benchmarking Tool has 
been developed, allowing healthcare professionals 
and, for the first time, patients the ability to rate, 
compare and benchmark the quality of IBD care 
provided across the UK.
How might this study impact on clinical practice in 
the foreseeable future?
 Ź The IBD Standards and online Benchmarking 
Tool provide a strong patient-centred framework 
for ongoing service development and quality 
improvement in UK-wide IBD care. Through enhanced 
partnership between patients and healthcare 
professionals, this tool has the potential to address 
inequalities in healthcare provision, to enhance shared 
decision-making and to promote the development of 
personalised care models
the recognition of the potential impact of improving 
patient care and outcomes at a local level, and the 
commitment of both healthcare professionals and 
patients to working in partnership to measure current 
delivery and effect meaningful change.
Following the launch of the IBD Standards in June 
2019, the patient survey and IBD service web tool will 
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be completed. Data will be collected through the IBD 
UK website, and the data controller will be Crohns & 
Colitis UK. The intention is for both patient survey and 
IBD service reports to be publicly available from the IBD 
UK website. The data will be used to inform IBD services 
and enable them to drive quality improvement, encour-
aging providers and patients to work in partnership.
CONCLUSION
The third UK IBD Standards comprise 59 consensus 
statements across seven clinical areas that make up the 
journey of patients with IBD. They have been developed 
by the IBD UK group, with patient involvement at all 
stages, and they represent the items that are necessary 
for delivery of a high-quality IBD service. They are inte-
grated with current UK IBD guidelines and endorsed 
by relevant professional bodies. They are supported 
by benchmarking tools that are appropriate for use by 
healthcare professionals and by patients. Using these 
tools, services can measure their own performance, 
obtain feedback from patients and compare their service 
with others, with the overall aim of driving up the quality 
of services supporting patients with IBD.
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